ArticleBMC pulmonary medicine2026
CircSPARC mediates an immunosuppressive tumor microenvironment by regulating the miR-199a-5p/LASP1 axis in non-small cell lung cancer.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a major cause of cancer-related mortality globally, linked to an immunosuppressive microenvironment. Circular RNA circSPARC is crucial in cancer, but its function in NSCLC remains unclear. 66 NSCLC tissue samples and 4 cell lines were analyzed for circSPARC and PD-L1 expression via qRT-PCR. A549 and H1299 cells were transfected with shRNA targeting circSPARC. THP-1 cells were differentiated into macrophages with phorbol 12-myristate-13-acetate (PMA). A549 and H1299 cells were co-cultured separately with CD8+T cells. Cell viability, invasion, expression of M2 macrophage markers (CD206, CD163), immune checkpoint (PD-L1), cytokines (IL-10, TGF-β, IFN-γ, TNF-α), and the proportion of CD8+ TNF-α+ T cells were analyzed by CCK-8 assay, Transwell, Western blot, ELISA, and flow cytometry. Dual-luciferase reporter and RNA pull-down assays were employed to confirm interactions between circSPARC, miR-199a-5p, and LASP1. Rescue experiments involved inhibiting miR-199a-5p or by overexpressing/silencing LASP1. Finally, the role of circSPARC was investigated in vivo using a subcutaneous tumor model. CircSPARC was highly expressed in NSCLC tissues and cells. circSPARC knockdown inhibited NSCLC cell viability, invasion, and reduced CD206 and CD163 expressions. Moreover, circSPARC knockdown reduced the excretion of immunosuppressive cytokines (IL-10 and TGF-β) as well as PD-L1 expression but promoting release of effector cytokines (IFN-γ and TNF-α) and increasing the proportion of CD8+ TNF-α+ T cells. Mechanistically, circSPARC sponged miR-199a-5p to upregulate LASP1. These findings were validated in a mouse xenograft model. The circSPARC/miR-199a-5p/LASP1 axis mediated the immunosuppressive microenvironment of NSCLC, highlighting circSPARC as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.